Grant: Engage Grants Program
Lakehead University
$25,000.00
Synthetic Toll-like Receptor 4 Agonists as Potential Adjuvants for Use in Animal Vaccines
EF 2011-12
Résumé
Adjuvants play an essential role in the development of new vaccines to combat life-threatening diseases in companion animals as well as livestock. Vaccine protection is a particular concern in agriculture where farming depends on maintaining health in herd animals. Improvement of existing animal vaccines with the development of novel adjuvants could also potentially increase their safety and efficacy. Currently there are only a few adjuvants available for vaccines in animal use, and therefore there is an urgent need to develop and characterize new adjuvants.
Immunovaccine (IMV) has developed the proprietary DepoVaxTM delivery technology and is currently developing vaccines for animal diseases. To address the company's need of new adjuvants for animal vaccines, we propose to synthesize a few lipid A mimics as adjuvant candidates, potentially targeting Toll-like receptor 4 (TLR4) to activate the innate immune response. Following the completion of their synthesis, these compounds will be formulated in DepoVaxTM and their biological efficacy as adjuvants evaluated. The proposed research will facilitate the establishment of research collaboration between the applicant and the industry partner, generate new intellectual properties, and result in the identification of new adjuvant candidates for the development of veterinary health products. The research outcome may eventually translate to significant economic and social benefits to Canada.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
428767-2011
Name nom
Jiang, ZiHua
Department département
Chemistry
Organization id
25
Institution établissement
Lakehead University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2011
Award amount
25000
Program id
EGP
Program nane en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
505
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Veterinary pharmaceuticals
Area of application fr
Produits pharmaceutiques à usage vétérinaire
Research subject code
3700
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic chemistry
Research subject fr
Chimie organique
Partie
1
Nb partie
1
Application title
Synthetic Toll-like Receptor 4 Agonists as Potential Adjuvants for Use in Animal Vaccines
Keyword
NSERC
Application summary
Adjuvants play an essential role in the development of new vaccines to combat life-threatening diseases in companion animals as well as livestock. Vaccine protection is a particular concern in agriculture where farming depends on maintaining health in herd animals. Improvement of existing animal vaccines with the development of novel adjuvants could also potentially increase their safety and efficacy. Currently there are only a few adjuvants available for vaccines in animal use, and therefore there is an urgent need to develop and characterize new adjuvants.
Immunovaccine (IMV) has developed the proprietary DepoVaxTM delivery technology and is currently developing vaccines for animal diseases. To address the company's need of new adjuvants for animal vaccines, we propose to synthesize a few lipid A mimics as adjuvant candidates, potentially targeting Toll-like receptor 4 (TLR4) to activate the innate immune response. Following the completion of their synthesis, these compounds will be formulated in DepoVaxTM and their biological efficacy as adjuvants evaluated. The proposed research will facilitate the establishment of research collaboration between the applicant and the industry partner, generate new intellectual properties, and result in the identification of new adjuvant candidates for the development of veterinary health products. The research outcome may eventually translate to significant economic and social benefits to Canada.